Whilst a number of AChE inhibitors that originate from natural sources have been developed into therapeutic agents for the treatment of AD, the number of BChE inhibitory therapeutics from the natural pool is substantially lower (Clive et al., 2005). The gene discussed is ACHE; the disease is Alzheimer disease.